170 related articles for article (PubMed ID: 34022459)
1. R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
Schuhmacher A; Wilisch L; Kuss M; Kandelbauer A; Hinder M; Gassmann O
Drug Discov Today; 2021 Aug; 26(8):1784-1789. PubMed ID: 34022459
[TBL] [Abstract][Full Text] [Related]
2. Reviving an R&D pipeline: a step change in the Phase II success rate.
Wu SS; Fernando K; Allerton C; Jansen KU; Vincent MS; Dolsten M
Drug Discov Today; 2021 Feb; 26(2):308-314. PubMed ID: 33129994
[TBL] [Abstract][Full Text] [Related]
3. Biotech R&D goes further afield.
Lawrence S
Nat Biotechnol; 2006 Sep; 24(9):1052. PubMed ID: 16964201
[No Abstract] [Full Text] [Related]
4. The 802 million dollars fallacy.
Hodgson J
Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
[No Abstract] [Full Text] [Related]
5. Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence.
Schuhmacher A; Gatto A; Kuss M; Gassmann O; Hinder M
Drug Discov Today; 2021 Oct; 26(10):2226-2231. PubMed ID: 33965571
[TBL] [Abstract][Full Text] [Related]
6. What are the economic barriers of antibiotic R&D and how can we overcome them?
Renwick M; Mossialos E
Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
[No Abstract] [Full Text] [Related]
7. Investigating investment in biopharmaceutical R&D.
Carter PH; Berndt ER; DiMasi JA; Trusheim M
Nat Rev Drug Discov; 2016 Oct; 15(10):673-4. PubMed ID: 27616295
[TBL] [Abstract][Full Text] [Related]
8. Commentary: Reconsidering Pharmaceutical Research and Development Investments.
Gagnon MA
Healthc Policy; 2023 Feb; 18(3):25-30. PubMed ID: 36917451
[TBL] [Abstract][Full Text] [Related]
9. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
[TBL] [Abstract][Full Text] [Related]
10. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
Schuhmacher A; Brieke C; Gassmann O; Hinder M; Hartl D
Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
[TBL] [Abstract][Full Text] [Related]
11. The productivity crisis in pharmaceutical R&D.
Pammolli F; Magazzini L; Riccaboni M
Nat Rev Drug Discov; 2011 Jun; 10(6):428-38. PubMed ID: 21629293
[TBL] [Abstract][Full Text] [Related]
12. Biotech slumps in Q1.
Lawrence S
Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
[No Abstract] [Full Text] [Related]
13. Bugs or drugs, tortoises or hares?
Jacobs T
Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
[No Abstract] [Full Text] [Related]
14. A rollercoaster ride.
Jacobs T
Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
[No Abstract] [Full Text] [Related]
15. Pharmaceutical portfolio management: global disease burden and corporate performance metrics.
Daems R; Maes E; Mehra M; Carroll B; Thomas A
Value Health; 2014 Sep; 17(6):732-8. PubMed ID: 25236997
[TBL] [Abstract][Full Text] [Related]
16. China's biotech experiments.
Hepeng J
Nat Biotechnol; 2005 Dec; 23(12):1472-3. PubMed ID: 16421994
[No Abstract] [Full Text] [Related]
17. Patentees research and development expenditure in Canada.
Li S; Tomalin A
J Pharm Pharm Sci; 2002; 5(1):5-11. PubMed ID: 12042113
[TBL] [Abstract][Full Text] [Related]
18. Analysis of pharma R&D productivity - a new perspective needed.
Schuhmacher A; Hinder M; von Stegmann Und Stein A; Hartl D; Gassmann O
Drug Discov Today; 2023 Oct; 28(10):103726. PubMed ID: 37506762
[TBL] [Abstract][Full Text] [Related]
19. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
Han E; Kim TH; Jeung MJ; Lee EK
Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
[TBL] [Abstract][Full Text] [Related]
20. A change in the market--investing in diagnostics.
Batchelder K; Miller P
Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
